trium, ovary) and in nonestrogen target tissues (prostate, pituitary, and thyroid glands; digestive tract; urinary tract; and thymus [3] ). The presence of ER in breast cancer is a wellestablished independent prognostic factor /4] and, in association with progesterone receptor (PgR), is a predictor of a tumor's response to hormonal therapy. Patients with ER-positive tumors tend to have a more favorable prognosis than patients with receptor-negative tumors [5] . The disease-free survival of ER+ and PgR+ stage 1 and 2 breast cancer patients is longer than that of patients whose tumors are negative for both receptors [6] . Moreover, 70-80% of breast cancer patients with tumor biopsies containing ER and PgR respond to endocrine treatment, compared with only 10% of patients with ER-negative and PgR-negative tumors [7] . ER status is therefore an important factor in predicting the hormone-responsiveness of a tumor. Two kinds of techniques are widely used for determining the ER status of a tumor: quantification of ER in cytosol extracts of tumor tissue, and immunohistochemistry with tissue sections. Immunohistochemistry, which involves anti-ER monoclonal antibodies, allows visualization of the tissue distribution and subcellular localization of ER by direct antigenic recognition [8, 9] . Nevertheless, this method has some disadvantages: It is not standardized, and results are at best only semiquantitative. Quantitative techniques performed on cytosol extracts of tumor tissue fall into two classes. The basic method for comparison is the radioligand assay (RLA), which is based on the binding of a specific tritiated ligand to unoccupied ERs, followed by removal of unbound material with dextran-coated charcoal. The displacement of tritiated estradiol by an excess of unlabeled diethylstilbestrol and the introduction of dihydrotestosterone in the incubation mixture allow all specific binding sites to he reached, which obviates interferences from nonspecific binding proteins. The main limitation of the RLA is the detection limit.
When anti-ER monoclonal antibodies became available, an enzyme immunoassay (EIA) of ER was developed (ER-EIA monoclonal kit from Laboratoires Abbott, Rungis, France) [10] 
Materials and Methods

SAMPLE COLLECTION
Receptors were measured in breast adenocarcinoma tissue biopsies. The samples were obtained from surgical specimens and immediately frozen in liquid nitrogen before transferal to the laboratory. None of the patients in this study had received chemo-or radiotherapy before surgical treatment.
REAGENTS
We used the following buffers: phosphate-buffered saline, 50 In each well 100 .tL of cytosol (pure or diluted in TEM buffer) or 100 .tL of standard (lyophilized standard reconstituted in deionized water and diluted in TEM buffer) was incubated with 100 .tL of buffer A.
After 16-to 18-h incubation at 4 #{176}C, during which the ERs bound to the antibodies, the contents of the wells were aspirated and the wells were washed (3 X 0.3 mL of 1 mL/L Tween 20 in deionized water) to remove unbound material. We then added to each well 200 .tL of horseradish peroxidase (HRP)-conjugated antibody diluted in buffer B, incubated the plate for 3 h at 4 #{176}C, and then aspirated and washed the wells as before. The HRP-conjugated antibody was a mouse anti-ER monoclonal antibody (AER314, TgG1; Bioprobe B.V., Amstelveen, The Netherlands) [17] directed against an epitope distinct from BlO in the B domain (region 121-168). We then added 100 jiL of the enzyme substrate solution (hydrogen peroxide and o-phenylenediamine-2HCI), incubated this for 30 mm at room temperature in the dark, and stopped the enzymatic reaction by adding 100 L of 1 mol/L sulfuric acid. The intensity of the coloration at 492 nm, which was proportional to the amount of receptor, was measured with a Spectra spectrophotometer (SLT Labinstruments, Grodig, Austria .tL of cytosol (diluted in TEM bufferto a protein concentration
into tubes. After a 30-mm incubation at room temperature in the dark with 300 .tL of the enzyme substrate solution (hydrogen peroxide and o-phenylenediamine-2 HCI), the enzymatic reaction was stopped by adding 1 mL of 0.5 mol/L sulfuric acid. The intensity of the color developed at 492 nm was measured with a Photocis IV spectrophotometer (CIS Bio International, Gif-sur-Yvette, France). The ER concentration of each tumor cytosol assayed was calculated by determining the corresponding concentration on the calibration curve and multiplying the value by a factor of 2.
PROTEIN
CONCENTRATION
The protein concentration of cytosols was determined with the BCA protein assay kit (Pierce Europe, Oud Beijerland, The Netherlands), according to the manufacturer's instructions. Bovine serum albumin (Sigma; Cohn Fraction IV) was used as the calibrator.
STATISTICAL ANALYSIS
The precision profile was established by using the Variance Function Package program /19] . Statistical analysis of the data was performed according to the method of Passing and Bablok [20, 21] .
Results
ASSAY CHARACTERISTICS
OF MICROTITER PLATE
E1A96
Calibration curve. Fig. 1 shows the calibration curve. The 250 pmol/L calibrator was obtained by reconstitution of a lyophilized recombinant human ER solution in distilled water (see above). The others (5, 25, and 100 pmol/L) were prepared by diluting the 250 pmol/L calibrator in TEM buffer. TEM buffer alone was the 0 pmol/L control. For each calibrator, the absorbance at 492 nm is greater than that observed with Abbott ER-EIA, indicating a slightly higher nonspecific binding of the HRP-conjugated antibody in EIA96; E1A96 A492 = 0.011; ER-ETA A49, = 0.002. 
. Typical calibration curves from EIA96 (U) and ER-EIA(s).
Precision. The within-assay CVs for three pools of human breast cancer cytosols(pools 1, 2, and 3) assayed 15 times (Table 1) were <5.0%, except for pool 1 (6.5 pmolfL), which had an intraassay CV of 6.7%. The interassay CVs for pool 2 and two other pools of human breast cancer cytosols (pools 4 and 5) assayed in duplicate or in triplicate in six separate experiments (Table 1) were 5.0%. Duplicate assays of cytosols prepared from tissue biopsies obtained from 100 patients with breast adenocarcinoma (Fig. 2, top) showed that, for ER concentrations 20 pmol/L, 23 of 40 cytosols (57.5%) showed CVs <10%; for ER concentrations >20 pmol/L, 4 of 60 cytosols (6.7%) had CVs >10%.
The detection limit was calculated from the precision profile (SD vs concentration; Fig. 2 , bottom) and was defined as the y-intercept of the profile /22]. The detection limit of the E1A96 was determined to be 0.58 pmol/L.
Dilution test.
A dilution test was performed by serially diluting in TEM buffer three pools of human breast cancer cytosols differing in ER content (pools 6, 7, and 8; see Table 2 ). Each dilution was tested in duplicate. The differences between each corrected ER concentration and the concentration of the nondiluted pools ranged between -14.1% and 1.7% for pool 6, between -12.4% and -4.5% for pool 7, and between -3.5% and -0.8% for pool 8. Bottom: The detection limit was defined as the intercept of the curve with the yaxis.
ASSAY COMPARISON STUDY WITH
TUMOR SAMPLES
Fifty of the 100 human breast cancer cytosols used for the precision study were assayed by all three methods (ETA96, RLA, and Abbott ER-ETA (Fig. 3) . As none of the variables could be assumed to be free of error, and as the variance of the measurement errors increased with the magnitude of the measurements, we used a linear regression procedure with no special assumptions regarding the distribution of the samples or of the measurement errors. The hypothesis slope = 1 and intercept = 0 was accepted for ETA96 vs ER-ETA (Fig. 3, top) , because the values of I and 0 were enclosed in the confidence intervals for the slope and the y-intercept, respectively. For ETA96 vs RLA (Fig. 3, middle) and ER-ETA vs RLA (Fig. 3, bottom) , the hypothesis was rejected.
Discrepancies in terms of positivity/negativity of the results were observed in three samples (Table 3) . We used a cutoff value of 15 finollmg protein, as in the ER-ETA kit. Cytosol A was then PgR concentration of cytosol D was 32 fmol/mg protein.
Discussion
250
Using two monoclonal antibodies directed against different epitopes in the B domain of the estrogen receptor, we developed an immunoenzymometric assay for ER. The sample concentration is read on a calibration curve constructed with a set of dilutions of a recombinant antigen standard solution (range 0-2 50 pmolIL) calibrated by reference to cytosols of mammary tumors assayed by RLA. Unlike the Abbott ER-ETA technique, ETA96 processes samples and standards in the same way (same first incubation volume and buffer). The calibration curve is linear, giving an absorbance at 492 nm of 2.014 for the 250 the functionality of the E domain. As for the samples that gave discrepant results by the three assays, many variant forms of ER have been described in human mammary tumors [23] as well as in normal breast tissue [24] . The vast majority of these variants arise from an alternative splicing of the mRNA, leading to deletion of whole exons, i.e., exons 2, 3, 4, 5, and 7. The proteins encoded by aberrantly spliced transcripts are truncated or internally deleted. Study of their functional behavior has shown most notably the existence of dominant-positive receptors, which are transcriptionally active in the absence of estrogen (e.g., an ER encoded by an exon 5-deleted mRNA [251), and a dominant-negative receptor (ER encoded by an exon 7-deleted mRNA [26, 27] ), which is transcriptionally inactive and prevents the action of wild-type ER.
The discrepancies found could be explained by the presence of variant forms of the receptor, which would be recognized differently by the three methods, depending on the localization of the mutation. The dispersion of the values obtained for cytosol D could result from the presence of a great quantity of estradiol, which, on the one hand, would not be totally displaced by RLA, and, on the other hand, would not inhibit the receptor recognition by EIAs. Thus, for ETA96, the epitopes are not in the E domain, and, for ER-ETA, the localization of one epitope 
